Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Peer Review reports

Original Submission
1 Nov 2017	Submitted	Original manuscript
22 Nov 2017	Author responded	Author comments - Kenichi Inoue
Resubmission - Version 2
22 Nov 2017	Submitted	Manuscript version 2
11 Apr 2018	Reviewed	Reviewer Report - William Jacot
21 Apr 2018	Reviewed	Reviewer Report - Elsa Curtit
11 May 2018	Author responded	Author comments - Kenichi Inoue
Resubmission - Version 3
11 May 2018	Submitted	Manuscript version 3
23 May 2018	Author responded	Author comments - Kenichi Inoue
Resubmission - Version 4
23 May 2018	Submitted	Manuscript version 4
Publishing
25 May 2018	Editorially accepted
20 Jun 2018	Article published	10.1186/s12885-018-4556-6

Back to article page